We are collaborating with ONO Pharmaceutical to develop and commercialize off-the-shelf CAR-T cell product candidates for the treatment of solid tumors. The collaboration brings together ONO’s global leadership and proven track record in oncology and our expertise with induced pluripotent stem cells (iPSC) and CAR-T cell therapies. Under the collaboration, using our proprietary iPSC platform, collaboration candidates will be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, include insertion of a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality.
In June 2022, we expanded our collaboration with Ono to include the research and development of CAR-targeted natural killer (NK) cell candidates derived from engineered master induced pluripotent stem cells for the treatment of solid tumors. We are jointly conducting research and development activities under a joint development plan and are developing product candidates against two solid tumor antigen targets.